Jul 6, 2026
Foundation plans to use results to guide future education and programs
Written by Andrea Lobo | June 23, 2026
- Top concerns of the Parkinson's community's include disease symptoms and medication knowledge, a survey found.
- Motor (tremor, gait, balance) and nonmotor (sleep, mood, cognitive) symptoms were most concerning.
- Respondents cited the need more information on symptoms/treatments, better care access, and increased research funding.
According to this year’s Parkinson’s Foundation State of the Community Survey, disease symptoms and medication knowledge are top concerns for the Parkinson’s disease community.
More than half of the participants identified motor symptoms (61%), especially tremor, gait, and balance issues, and nonmotor symptoms (52%), including sleep, mood, and cognitive problems, as the most concerning.
Participants also expressed interest in learning more about the disease symptoms, treatment options, and research updates. The foundation plans to use these data to guide future education and programs.
“I believe in narrative medicine, where I encourage patients to share their Parkinson’s story — focusing on the symptoms [that] affect them the most and working together to create a personalized care plan that empowers them to take an active role,” Sneha Mantri, MD, Parkinson’s Foundation chief medical officer, said in a press release.
Barriers include lack of knowledge on available services
This year, more than 9,000 responders, mainly people with Parkinson’s (70%), but also care partners, family members, friends, and health professionals across the U.S. and other countries, participated in the survey in English or Spanish. This represents a 30% jump from 2025. The survey provides a global overview of the community’s experiences and needs, according to the foundation.
Another challenge reported by participants was understanding which questions to ask and symptoms to talk about with their healthcare team. Many considered it difficult to discuss mental and emotional health. Most people also noted only spending 15 to 30 minutes with their provider.
The most commonly reported barriers included a lack of knowledge on available services and how to access them, and difficulties getting appointments or having to travel long distances to get care. For Spanish speakers, barriers included service costs, language issues, and insufficient available services.
Continue Reading Here
Jul 3, 2026
NeuroEXPLORER can image small brain regions involved in the disease
Written by Andrea Lobo | June 18, 2026
- NeuroEXPLORER PET can image small, deep brain regions involved in Parkinson’s and other conditions.
- The scanner may help detect early brain changes linked to neurodegenerative diseases and support more precise diagnosis.
- It may aid DBS planning and help researchers monitor how treatments affect targets in the brain.
UZ Leuven and KU Leuven, two institutions in Belgium, have introduced NeuroEXPLORER PET into clinical practice. The ultra-high-resolution PET scanner, developed by United Imaging Healthcare, is designed to visualize small, deep brain regions, including those involved in Parkinson’s disease.
Within the first six months, the system supported imaging in more than 400 patients. UZ Leuven also is using the scanner in an ongoing comparative clinical trial to assess its added value over existing PET scanners. Over the next five years, the scanner will support more than 30 large-scale research programs across neurodegeneration, neuromodulation, and inflammation, among others.
Scanner enters clinical use in Belgium
“This technology fundamentally changes how we can investigate the origins and diagnoses of neurological and psychiatric diseases, as well as vascular diseases and head- and neck disorders such as tumours,” Koen Van Laere, MD, PhD, professor at KU Leuven and principal investigator, said in a company press release from United Imaging Healthcare. “It allows us to measure disease processes in very small structures with unprecedented precision.”
Mathieu Vandenbulcke, MD, PhD, chair of the Leuven Brain Institute, added, “The NeuroEXPLORER strengthens Leuven’s international position in brain research and precision medicine. It creates a unique platform for global scientific collaboration.”
Parkinson’s disease is caused by the progressive dysfunction and loss of dopaminergic neurons, the nerve cells that produce dopamine, a signaling molecule that allows nerve cells to communicate. These neurons are primarily found in the substantia nigra, a region deep in the brain involved in movement control.
Diagnosing the disease may involve the use of markers of dopamine signaling in high-resolution PET scans to assess dopaminergic function, which may help distinguish Parkinson’s patients from those with other conditions causing similar symptoms.
The NeuroEXPLORER PET scanner uses low-level radioactive tracers to visualize subtle biological and chemical changes in the brain, including deep brain regions, with resolution up to 20 times higher than conventional PET scanners.
Continue Reading Here
Recent Comments